GlaxoSmithKline (GSK) has completed its $2-billion acquisition of Bellus Health, a Laval, Quebec, Canada-based, bio/pharmaceutical company.  The companies had announced the acquisition in April (April 2023).  

Bellus’ lead drug candidate is camlipixant, in Phase III development, for the first-line treatment of adult patients with refractory chronic cough, defined as a cough that persists for more than eight weeks despite optimal treatment of any underlying conditions or where there is no identifiable underlying cause.  

Source: GlaxoSmithKline